News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Funding to grow the insurance and digital therapeutics vertical in India
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh
The newly launched centre in Mumbai is part of the company’s ambition to be present in 100 cities across the country within two years.”
Subscribe To Our Newsletter & Stay Updated
